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Abstract
Background: China has the highest absolute disease burden of diabetes worldwide. For diabetic patients, diabetes-
related vascular complications are major causes of morbidity and mortality. The roles of lipoprotein-associated
phospholipase A2 (Lp-PLA2) and secretory phospholipase A2 (sPLA2) as inflammatory markers have been recently
evaluated in the pathogenesis of both diabetes and atherosclerosis. We aimed to determine the mechanism
through which patients with newly diagnosed type 2 diabetes gain long-term vascular benefit from intensive
insulin therapy by evaluating the change in Lp-PLA2 and sPLA2 levels after early intensive insulin treatment and its
relevance with insulin resistance and pancreatic β-cell function.
Methods: In total, 90 patients with newly diagnosed type 2 diabetes mellitus were enrolled. All patients received
continuous subcutaneous insulin infusion (CSII) for approximately 2 weeks. Intravenous glucose-tolerance test
(IVGTT) and oral glucose-tolerance test (OGTT) were performed, and plasma concentrations of Lp-PLA2 and sPLA2
were measured before and after CSII.
Results: Levels of Lp-PLA2 and sPLA2 were significantly higher in diabetic patients with macroangiopathy than in
those without (P < 0.05). After CSII, the sPLA2 level decreased significantly in all diabetic patients (P < 0.05), while the
Lp-PLA2 level changed only in those with macroangiopathy (P < 0.05). The area under the curve of insulin in IVGTT
and OGTT, the acute insulin response (AIR3–5), early phase of insulin secretion (ΔIns30/ΔG30), modified β-cell
function index, and homeostatic model assessment for β-cell function (HOMA-β) increased after treatment even
when adjusted for the influence of insulin resistance (IR; P < 0.001). The HOMA-IR was lower after treatment, and the
three other indicators adopted to estimate insulin sensitivity (ISIced, IAI, and QUICKI) were higher after treatment
(P < 0.05). Correlation analysis showed that the decrease in the Lp-PLA2 and sPLA2 levels was positively correlated
with a reduction in HOMA-IR after CSII (P < 0.05). Additionally, multiple linear regression analysis showed that
Lp-PLA2 and sPLA2 independently correlated with HOMA-IR (P < 0.05).
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Conclusions: Lp-PLA2 and sPLA2 are closely related to insulin resistance and macroangiopathy in diabetic patients.
Intensive insulin therapy might help improve IR and protect against diabetic macroangiopathy by influencing the
Lp-PLA2 and sPLA2 levels.
Trial registration: ChiCTR-TRC-10001618 2010 September 16.
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Background
Currently, China is one of the countries with the highest
prevalence of diabetes in Asia and has the largest absolute
disease burden of diabetes worldwide. According to the
most recent epidemiological survey, the overall prevalence
of diabetes was estimated to be 11.6% in Chinese adults
[1]. Diabetes-related vascular complications such as car-
diovascular disease and stroke are major causes of morbid-
ity and mortality for type 2 diabetic patients (T2DM) [2].
Inflammatory processes have been found to play a role in
the pathogenesis of both diabetes and atherosclerosis, and
may offer a biological link between the two diseases [3].
Various circulating markers of inflammation have been ex-
tensively evaluated for their role as risk predictors of dia-
betes and atherosclerosis [4–6]. Among these markers,
lipoprotein-associated phospholipase A2 (Lp-PLA2)
and secretory phospholipase A2 (sPLA2) have gained
considerable interest in the last decade. Many pro-
spective studies have also indicated that Lp-PLA2 and
sPLA2 are independent predictors of coronary heart dis-
ease and carotid stenosis, and they are more closely asso-
ciated with atherosclerosis as compared to classic
inflammatory markers such as C-reactive protein [7, 8].
Lp-PLA2 and sPLA2 are two subtypes of the PLA2 super-
family, a family of enzymes that propagate inflammation by
catalyzing the hydrolysis of glycerophospholipids, thereby
producing non-esterified fatty acids (FA) such as arachidonic
acid. Lp-PLA2, also known as platelet-activating factor acet-
ylhydrolase, is a 50-kD Ca2+-independent phospholipase
and hydrolyzes phospholipids to produce free FAs (FFAs)
and lyso-phosphatidycholine, thus promoting inflammation
and atherosclerosis. Another important extracellular enzyme
of the PLA2 superfamily, sPLA2, is a 14-kD Ca
2+-dependent
phospholipase and is normally expressed in arterial walls. Its
expression is readily upregulated by inflammatory stimuli,
suggesting a potential role in the early phases of response to
vessel injury. Most studies have attributed an inflammatory
role to Lp-PLA2 and sPLA2 [9, 10]. In addition, studies sug-
gest that Lp-PLA2 is positively associated with insulin resist-
ance and predicts the incidence of T2DM [11]. However,
few study has assessed the effect of glycemic status of the
patients on sPLA2. Moreover, other studies showed that
both of Lp-PLA2 and sPLA2 play critical roles in the devel-
opment of atherosclerosis and its clinical sequelae [7]. Lp-
PLA2 and sPLA2 are upregulated in atherosclerotic plaques
and are strongly expressed in macrophages within the
fibrous cap of rupture-prone lesions [7, 12].
Short-term intensive insulin therapy can induce effective
glycemic control and improve islet function and insulin
sensitivity in patients with newly diagnosed T2DM [13]. In
the United Kingdom Prospective Diabetes Study (UKPDS),
after a 10-year follow-up, patients with newly diagnosed
T2DM who received intensive glucose therapy were found
to have a reduced risk of microvascular complications, cor-
onary events, and death from any cause [14]. However, the
mechanism through which these patients benefit from in-
tensive insulin therapy is poorly understood. To our know-
ledge, no study has thus far specifically assessed the effect
of intensive insulin therapy on Lp-PLA2 and sPLA2 levels
in patients with newly diagnosed T2DM. Therefore, this
study aimed to evaluate the change in Lp-PLA2 and sPLA2
levels after intensive insulin treatment and the correlation
of these two enzymes with insulin resistance and pancreatic
β-cell function in patients with newly diagnosed T2DM.
Methods
Subjects
Patients with newly diagnosed T2DM were enrolled in
this study at the Sun Yat-sen Memorial Hospital of Sun
Yat-sen University from October 2010 to March 2012.
Diabetes was diagnosed in accordance with the diagnostic
criteria of American Diabetes Association (ADA, 2010).
All patients were 30–60 years of age, negative for pancre-
atic islet autoantibody, and had never taken hypoglycemic
drugs. Patients with acute hyperglycemic complications,
severe hepatic disease, renal dysfunction, cardiac dysfunc-
tion, and acute or chronic infections were excluded.
Research design
This was a self-control study of patients with newly di-
agnosed T2DM. All the enrolled diabetic patients were
admitted to the hospital. The same researcher measured
the height, weight, waist circumference, and blood pres-
sure of the subjects on an empty stomach using consoli-
dated tools. Body mass index (BMI) was calculated as
weight divided by the square of the height (kg/m2). After an
overnight fast, venous blood samples were drawn for meas-
uring blood glucose, hemoglobin A1c (HbA1c), lipid pro-
files (including total cholesterol [TC], triglyceride [TG],
high-density lipoprotein cholesterol [HDL-C], and low-
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density lipoprotein cholesterol [LDL-C]), traditional inflam-
matory markers (including white blood cells [WBC], FFA,
and high-sensitivity C-reactive protein [hsCRP]), Lp-PLA2,
and sPLA2. Subsequently, the patients underwent an intra-
venous glucose-tolerance test (IVGTT) with 50 mL of 50%
glucose solution using the standard protocol. Blood
samples were collected before and 3, 5, 7, and 10 min
after the injection to assess the glycemic and insulin
status. The next day, patients underwent the oral
glucose-tolerance test (OGTT) with 75-g glucose load.
To determine the glycemic and insulin status, blood
samples were obtained before and 30, 60, 120, and
180 min after oral administration.
Thereafter, the patients received insulin lyspro (Humalog
Lilly, USA) via an insulin-infusion pump (MiniMed 712)
for approximately 2 weeks. The initial insulin doses were
0.4–0.6 IU/kg/day. Total daily doses were divided into 50%
basal and 50% bolus injection. The doses of bolus and
basal insulin infusions were adjusted according to the ca-
pillary blood glucose levels. Patients were asked to monitor
their glycemic levels before and 2 h after each meal, and at
bedtime. The target blood glucose level was defined as
fasting plasma glucose (FPG) level < 6.1 mmol/L and 2-h
postprandial plasma glucose (2hPG) level < 7.8 mmol/L. A
severe hypoglycemic episode (PG <2.8 mmol/L) was
defined as an event requiring the assistance of another
person to actively administer carbohydrate, glucagon, or
other resuscitative treatments. No oral hypoglycemic
agents, antiplatelet medicine, or lipid drugs were adminis-
tered during the study. Antihypertensive drugs affecting
the renin-angiotensin system were also avoided in patients
with complications of hypertension. Twenty-four hours
after completion of the treatment, all the measurements
mentioned above were reviewed.
Laboratory analyses
For plasma samples, blood was collected in EDTA vials and
plasma was separated by centrifugation at 1000 × g for
10 min. The plasma samples were stored at −80°C and
analyzed later for the mass of Lp-PLA2 and sPLA2.
Concentrations of Lp-PLA2 and sPLA2 were assayed using
a double-antibody sandwich enzyme-linked immunosorb-
ent assay kit (Uscn Life Science, Peking, China). Three
repetitive experiments showed that the average of coeffi-
cient of variation within-run was below 5%.
The plasma glucose level was determined by the
glucose-oxidase method using a semi-automatic bio-
chemistry analyzer (GF-D200, Shandong, China). The
HbA1c concentration was measured using high-pressure li-
quid chromatography (BIO-RAD, California, USA). The
direct chemiluminescence method was used to meas-
ure serum insulin levels with an automatic biochemis-
try analyzer (Immulite 2000, DPC, USA). The lipid profiles
were measured by enzymatic colorimetry using a semi-
automatic biochemistry analyzer (GF-D200, Shandong,
China). Homeostasis model assessment (HOMA) was used
to estimate insulin resistance (HOMA-IR) and β-cell func-
tion (HOMA-β) as follows: HOMA-IR = FPG× fasting in-
sulin (FINS)/22.5 and HOMA-β = 20 × FINS/(FPG - 3.5).
Other indicators used to evaluate β-cell function were as
follows. The acute insulin response (AIR) was used to as-
sess the first-phase insulin secretion, including the average
increase in plasma insulin levels between the third or fifth
minute and the baseline (AIR3–5) during IVGTT. The area
under the curve of insulin (AUCIns) was calculated as the
incremental trapezoidal area during the first 10 min as fol-
lows: IVGTT AUCIns = (3 × FINS + 5 × INS3 + 4 × INS5 +
5 × INS7 + 3 × INS10)/2. The early phase of insulin secretion
was expressed as ΔINS30/ΔG30 = (INS30 - FINS)/(G30 -
FPG). The second-phase of insulin release was indicated as
AUCIns during OGTT and was calculated as OGTT
AUCIns = (FINS + 2 × INS30 + 3 × INS60 + 4 × INS120 + 2 ×
INS180)/4. Modified β-cell function index (MBCI) was cal-
culated as MBCI = (FPG× FINS)/(G120 +G60 - 7) and was
used for comprehensive assessment of β-cell function.
Moreover, three other indicators were adopted to estimate
insulin sensitivity: IAI, (calculated as 1/[FINS × FPG]),
QUICKI (calculated as 1/[lgFPG+ lgFINS]), and ISIced (cal-
culated as MCR/LgMSI, MCR=M/MG, MG= [G0min +
G30 min +G60 min +G120 min]/4, MSI = [I0 min + I30 min + I60
min + I120 min]/4, M = 75000/120 + [G0 min - G120 min] ×
1.15 × 180 × 0.19 × body weight/120). In addition, all the in-
dicators for β-cell function were divided by HOMA-IR to
exclude interference of insulin resistance [15]. Furthermore,
ultrasonography and electrocardiography were performed
to screen atherosclerosis in the lower limbs (whether fem-
oral artery or posterior tibial artery had definite plaques),
cervical vessels (whether carotid intima-media thickness
was more than 1.2 mm), and coronary artery (whether
ECG had changes of ST-T which indicated myocardial
ischemia).
Statistical analysis
Statistical analysis was performed using SPSS 13.0 soft-
ware for windows. Values of variables are expressed as
mean ± standard deviation (SD) if their data fit the nor-
mal distribution and as median (interquartile range) if
their data did not fit the normal distribution. Change in
the variables after treatment was assessed using a paired
t-test or Wilcoxon rank sum test. Pearson or Spearman’s
rank correlation analysis was used to assess the asso-
ciation between variables. Multiple linear regression
analysis was used with HOMA-IR as a dependent
variable. Variables that had skewed distributions were
logarithmically transformed (lg10). A two-sided value
of P < 0.05 was considered statistically significant in
all analyses.
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Results
Baseline characteristics
A total of 90 patients were enrolled in our study. The
mean age of the patients was 48.11 ± 9.21 years, and the
sex ratio (M/F) was 66:24. The FPG, 2hPG, and HbA1c
levels were 11.79 ± 3.57 mmol/L, 24.28 ± 5.90 mmol/L,
and 11.70% ± 2.40%, respectively. Waist circumference
was 87.49 ± 8.26 cm (normal range in Chinese: <85 cm
for men and <80 cm for women), and BMI was 24.03 ±
2.93 kg/m2 (normal range in Chinese: 18.5 ~ 23.9 kg/m2).
Blood pressure was (129 ± 14)/(83 ± 10) mmHg. Lipid
profiles were as follows: TC was 5.82 ± 1.21 mmol/L,
TG was 1.76(1.26, 3.05)mmol/L, HDL-C was 1.18 ±
0.29 mmol/L, and LDL-C was 3.73 ± 0.98 mmol/L.
Traditional inflammatory markers like hsCRP, WBC
and FFA were 1.84(1.08,3.67)mg/L, 7.62 ± 2.02 × 109/L,
607.48 ± 225.00 umol/L, respectively. Tests for dia-
betic angiopathy showed that 14, 9, and 6 patients
had atherosclerosis in the lower limbs, cervical ves-
sels, and coronary artery, respectively (including two
patients with atherosclerosis both in the lower limbs
and cervical vessels and one patient with atheroscler-
osis both in the lower limbs and coronary artery).
Changes in the clinical features of diabetic patients after
intensive insulin treatment
Ideal glucose control was attained in 4.1 ± 2.0 days and
was maintained for 10.0 ± 2.4 days. The maximum dosage
of insulin administered was 50.32 ± 13.23 U/day (0.72
[0.64, 0.89] U/kg/day). The frequency of hypoglycemia
(≤3.9 mmol/L) during CSII treatment was 2 (1, 3) times.
There were no severe hypoglycemic (<2.8 mmol/L) epi-
sodes during the short-term intensive interventions. After
treatment, the measures of waist circumference, blood
pressure, HbA1c, AUC of glucose (AUCGlu) of IVGTT
and OGTT, TC, TG, LDL-C, and inflammatory markers
(including WBC and FFA, but not hsCRP) decreased sig-
nificantly (P < 0.05), whereas the levels of HDL-C and
AUCIns of IVGTT and OGTT increased significantly after
CSII (P < 0.05) (Table 1).
With regard to the insulin-secretory function of islets,
none of the diabetic patients showed first-phase insulin
secretion, and the peak of second-phase secretion ap-
peared later than it normally does (120 min vs. 60 min,
respectively). After 2 weeks of CSII, the levels of insulin
at each time point in both IVGTT and OGTT were sig-
nificantly elevated (P < 0.001) and the first-phase insulin
secretion was recovered, whereas the peak of second-
phase secretion was delayed (Fig. 1). Indicators of β-cell
function including AIR3–5, ΔINS30/ΔG30, HOMA-β, and
MBCI significantly improved after treatment (P < 0.05).
The results remained the same when they were divided
by HOMA-IR to exclude the influence of insulin resist-
ance (P < 0.001) (Table 1).
With respect to insulin resistance, the HOMA-IR de-
creased significantly after treatment, but the IAI, QUICKI,
and ISIced significantly improved after treatment (P < 0.001)
(Table 1).
Plasma levels of Lp-PLA2 and sPLA2 in diabetic patients
and their changes after CSII
The plasma levels of Lp-PLA2 and sPLA2 were 102.98
(76.34, 134.31) ng/mL and 219.33 (130.03, 337.30) ng/
mL, respectively, in diabetic patients before CSII. In
addition, the plasma levels of Lp-PLA2 and sPLA2 in
diabetic patients with evidence of atherosclerosis were
significantly higher than those in diabetic patients with-
out evidence of atherosclerosis (Lp-PLA2 levels: 133.43
[111.54, 145.17] ng/mL vs. 99.11 [63.02, 130.85] ng/mL;
sPLA2 levels: 235.73 [180.48, 416.46] ng/mL vs. 182.97
[90.08, 280.79] ng/mL, respectively, P < 0.001) (Fig. 2a). The
differences within and among product batches were <10
and <12%, respectively.
The plasma sPLA2 level was significantly reduced after
CSII in diabetic patients (from 219.33 [130.03, 337.30] ng/
mL to 173.78 [80.95, 278.09] ng/mL; P < 0.05) (Table 1,
Fig. 2b), regardless of whether they had macroangiopathy
or not (from 235.73 [180.48, 416.46] ng/mL to 183.76
[93.88, 271.54] ng/mL, P < 0.01; and from 182.97 [90.08,
280.79] ng/mL to 147.88 [76.58, 265.66] ng/mL, P < 0.05)
(Fig. 2c). However, we did not find any statistical differ-
ence in the plasma Lp-PLA2 level after treatment in all
diabetic patients (from 102.98 [76.34, 134.31] ng/mL to
88.35 [76.74, 125.18] ng/mL, P = 0.087) (Table 1, Fig. 2b).
Further analysis showed that the decrease of Lp-PLA2
level after treatment in diabetic patients with macroangio-
pathy was statistically significant (from 133.43 [111.54,
145.17] ng/mL to 92.16 [80.26, 128.78] ng/mL, P <0.05),
while it was not the case in those without macroangiopa-
thy (from 99.11 [63.02, 130.85] ng/mL to 85.94 [60.53,
119.76] ng/mL, P >0.05) (Fig. 2c).
Correlation analysis
In patients with newly diagnosed T2DM before CSII, the
Lp-PLA2 level was positively correlated with the HbA1c
concentration (r = 0.283, P = 0.020), LDL-C level (r = 0.269,
P = 0.029), and HOMA-IR (r = 0.309, P = 0.037). Correl-
ation analysis for sPLA2 and clinical parameters showed a
significant correlation of sPLA2 with waist circumference
(r= 0.243, P = 0.043) and HOMA-IR (r = 0.506, P <0.01).
No significant correlation was observed between the
Lp-PLA2 or sPLA2 levels and BMI, blood pressure,
TC, TG, HDL-C, all indicators used to evaluate β-cell
function, and other inflammatory factors (WBC, FFA,
and hsCRP) (Table 2).
After CSII, the decrease in the Lp-PLA2 (ΔLp-PLA2)
and sPLA2 (ΔsPLA2) levels were both positively co-
rrelated with the reduction in HOMA-IR (ΔHOMA-IR)
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Table 1 Clinical features of 90 newly diagnosed type 2 diabetic patients at baseline and after CSII
Baseline After CSII kind of test P
Waist circumference (cm) 87.49 ± 8.26 86.80 ± 7.93 paired t-test 0.021
Body mass index (kg/m2) 24.03 ± 2.93 23.85 ± 2.90 paired t-test 0.149
Systolic pressure (mmHg) 129 ± 14 121 ± 11 paired t-test <0.01
Diastolic pressure (mmHg) 83 ± 10 76 ± 7 paired t-test <0.01
HbA1c (%) 11.70 ± 2.40 9.82 ± 2.02 paired t-test <0.01
IVGTT AUCGlu 89.43 ± 17.38 67.01 ± 11.74 paired t-test <0.01
OGTT AUCGlu 79.57 ± 18.88 46.49 ± 9.28 paired t-test <0.01
Total cholesterol (mmol/L) 5.82 ± 1.21 4.89 ± 0.95 paired t-test <0.01
Triglyceride (mmol/L) 1.76 (1.26,3.05) 1.74 (1.29,2.24) Wilcoxon rank sum test 0.026
HDL-C (mmol/L) 1.18 ± 0.29 1.23 ± 0.29 paired t-test 0.035
LDL-C (mmol/L) 3.73 ± 0.98 2.93 ± 0.77 paired t-test <0.01
hsCRP (mg/L) 1.84 (1.08,3.67) 1.69 (0.77,2.96) Wilcoxon rank sum test 0.54
White blood cells (×109/L) 7.62 ± 2.02 6.75 ± 1.70 paired t-test <0.01
Free fatty acid (umol/L) 607.48 ± 225.00 469.11 ± 171.41 paired t-test 0.004
HOMA-IR 1.45 (1.01, 2.45) 0.96 (0.68, 1.85) Wilcoxon rank sum test <0.01
IAI 0.03 (0.02, 0.04) 0.05 (0.02, 0.06) Wilcoxon rank sum test <0.01
QUICKI 0.67 ± 0.12 0.74 ± 0.15 paired t-test <0.01
ISIced 5.89 (4.33, 7.26) 9.68 (8.25, 11.69) Wilcoxon rank sum test <0.01
HOMA-β 6.87 (4.40, 15.73) 21.00 (12.90,43.04) Wilcoxon rank sum test <0.01
AIR3–5 1.38 (0, 5.25) 3.80 (0.87,7.46) Wilcoxon rank sum test <0.01
ΔIns30/ΔG30 0.19 (0, 1.01) 1.80 (0.60, 3.29) Wilcoxon rank sum test <0.01
MBCI 0.91 (0.73, 1.70) 1.12 (0.74, 2.15) Wilcoxon rank sum test 0.048
IVGTT AUCIns 11.91 (8.00,29.05) 25.64 (10.32,46.79) Wilcoxon rank sum test <0.01
OGTT AUCIns 27.60 (12.20,64.37) 75.45 (46.37,123.53) Wilcoxon rank sum test <0.01
HOMA-β/HOMA-IR 4.84 (2.60, 9.59) 20.99 (12.50,31.78) Wilcoxon rank sum test <0.01
AIR3–5/HOMA-IR 0.95 (0, 2.86) 2.49 (0.45, 6.22) Wilcoxon rank sum test <0.01
ΔIns30/(ΔG30× HOMA-IR) 0.16 (0, 0.37) 1.11 (0.50, 2.75) Wilcoxon rank sum test <0.01
MBCI/HOMA-IR 0.71 (0.55, 0.92) 1.16 (1.01,1.34) Wilcoxon rank sum test <0.01
IVGTT AUCIns/
HOMA-IR
9.98 (6.58, 14.82) 21.25 (12.62,31.92) Wilcoxon rank sum test <0.01
OGTT AUCIns/HOMA-IR 17.91 (10.01,35.70) 64.35 (47.82,93.13) Wilcoxon rank sum test <0.01
Lp-PLA2 (ng/ml) 102.9 (76.34,134.31) 88.35 (76.74,125.18) Wilcoxon rank sum test 0.087
sPLA2 (ng/ml) 219.33 (130.03,337.30) 173.78 (80.95,278.09) Wilcoxon rank sum test <0.01
Abbreviations: HbA1c hemoglobin A1c, IVGTT AUCGlu the areas under the curve of glucose in intravenous glucose tolerance test, OGTT AUCGlu the areas under the
curve of glucose in oral glucose tolerance test, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, hsCRP high sensitivity C
reactive protein; HOMA-IR, IAI, QUICKI and ISIced are indicators of insulin sensitivity (HOMA-IR = FPG × FIns/22.5; IAI = 1/(FIns × FPG); QUICKI = 1/(lgFPG + lgFIns);
ISIced = MCR/LgMSI, MCR =M/MG, MG = (FPG + Glu30 min + Glu60 min + Glu120 min)/4, MSI = (FIns + Ins30 min + Ins60 min + Ins120 min)/4, M = 75000/120 +
(FPG - Glu120 min) × 1.15 × 180 × 0.19 × body weight/120), HOMA-β, AIR3–5 ΔIns30/ΔG30, MBCI, IVGTT AUCIns and OGTT AUCIns are indicators of island function
(HOMA-β = 20 × FIns/(FPG - 3.5); AIR3–5 is calculated as the average increase of plasma insulin between the 3rd or 5th minute and the base line in IVGTT; ΔIns30/
ΔG30 = (Ins30min - FIns)/(Glu30min - FPG); MBCI = (FPG × FIns)/(Glu120min + Glu60min - 7); AUCIns, the area under the curve (AUC) of insulin, IVGTT AUCIns = (3 ×
FINS+ 5 × INS3+ 4 × INS5+ 5 × INS7+ 3 × INS10)/2, OGTT AUCIns = (FINS + 2 × INS30+ 3 × INS60+ 4 × INS120+ 2 × INS180)/4; all the indicators regarding to β cell
function were respectively divided by HOMA-IR to guarantee from interference of insulin resistance), Lp-PLA2 lipoprotein-associated phospholipase A2, sPLA2
secretory phospholipase A2
Data are expressed as median (interquartile range) or mean ± SD
Values of P < 0.05 are statistically significant
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(r = 0.590, P < 0.05 and r = 0.476, P < 0.05, respectively)
(Fig. 3a, 3b). Further, multiple linear regression analysis
showed that both Lp-PLA2 and sPLA2 levels were inde-
pendent factors that were correlated with HOMA-IR
(β = 0.372 and β = 0.560 respectively, P < 0.05).
Discussion
Early intensive insulin therapy could effectively reduce
glucotoxicity and lipotoxicity, protect islet function, and
alleviate insulin resistance in patients with newly diag-
nosed T2DM [13]. Using comprehensive indicators, our
study showed that early intensive insulin treatment
could not only reduce waist circumference, blood pres-
sure, blood glucose (FPG, 2-h postprandial PG, HbA1c
concentration, AUCGlu during both IVGTT and OGTT),
blood lipid levels (TG, TC, and LDL-C), levels of trad-
itional inflammatory factors (WBC and FFA), and insulin
resistance (HOMA-IR), but also distinctly improve the
HDL-C levels, insulin sensitivity (IAI, QUICKI, and
ISIced) and β-cell function (HOMA-β, MBCI, AIR3–5,
ΔIns30/ΔG30, and AUCIns during IVGTT and OGTT) in
patients with newly diagnosed T2DM.
In the present study, the plasma concentration of Lp-
PLA2 was positively correlated with the HbA1c concentra-
tion in patients with T2DM during the early stages of
disease, which may indicate an important role of Lp-PLA2
in predicting T2DM [11]. The relationship between sPLA2
and the risk of diabetes is still unclear, and studies with a
larger sample size are needed to confirm this relationship.
In addition, Lp-PLA2 and sPLA2 levels were significantly
increased in diabetic patients with macroangiopathy as
compared to those without macroangiopathy. This finding
is consistent with the view that Lp-PLA2 and sPLA2 are im-
portant risk predictors for atherosclerosis [7, 16]. However,
it is uncertain whether plasma Lp-PLA2 and sPLA2 could
be markers of subclinical atherosclerosis for diabetic pa-
tients [17, 18]. In our study, we found positive correlations
between these two enzymes and several atherogenic factors
such as LDL-C, waist circumference, and IR in patients
with newly diagnosed diabetes. Therefore, we propose that
Fig. 1 Concentrations of blood glucose and insulin during IVGTT and OGTT before and after CSII (n = 90). a Means ± SD for glucose concentrations
during IVGTT before (■) and after CSII (▲). The AUCGlu in IVGTT decreased significantly (89.43 ± 17.38 mmol · min vs. 67.01 ± 11.74 mmol · min, P < 0.01)
after CSII. b Median (interquartile range) for insulin concentrations during IVGTT before (■) and after CSII (▲). The AUCIns in IVGTT was significantly
elevated (11.91 [8.00, 29.05] mU · min vs. 25.64 [10.32, 46.79] mU · min, P < 0.01) after CSII. c Means ± SD for glucose concentrations during OGTT before
(■) and after CSII (▲). AUCGlu in OGTT decreased significantly (79.57 ± 18.88 mmol · min vs. 46.49 ± 9.28 mmol · min, P < 0.01) after CSII. d Median
(interquartile range) for insulin concentrations during OGTT before (■) and after CSII (▲). AUCIns in OGTT was significantly elevated (27.60 [12.20, 64.37]
mU · min vs. 75.45 [46.37, 123.53] mU · min, P < 0.01) after CSII. Values of P < 0.05 are statistically significant. CSII, continuous subcutaneous insulin
infusion; IVGTT, intravenous glucose-tolerance test; OGTT, oral glucose-tolerance test; SD, standard deviation; AUCGlu, area under the curve of glucose;
AUCIns, area under the curve of insulin
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Lp-PLA2 and sPLA2 may affect the incidence of athero-
sclerosis in diabetic patients. A recent study suggested that
the relative distribution of Lp-PLA2 between LDL and
HDL determines its pro- or anti-inflammatory action. Ac-
cording to this assumption, Lp-PLA2 is anti-inflammatory
when bound to HDL, but pro-inflammatory when bound
to LDL [19]. Moreover, an increase in the binding between
Lp-PLA2 and LDL was observed in diabetic patients [20],
which could support the pro-atherosclerotic role of Lp-
PLA2 in diabetes. However, studies on sPLA2 in diabetic
patients are lacking in the literature.
Currently, animal experiments and clinical trials in-
volving an Lp-PLA2 inhibitor (darapladib) are underway
and have been shown to reduce the progression of ath-
erosclerosis in animals [21, 22] but not in humans [23]
with or without diabetes. On the other hand, studies on
a sPLA2 inhibitor (varespladib) showed that administra-
tion of 500 mg daily for 8 weeks could significantly reduce
the post-ACS (acute coronary syndrome) inflammatory
response, especially in diabetic patients [24]. In our study,
we aimed to determine whether intensive insulin treat-
ment could reduce the levels of Lp-PLA2 and sPLA2 in
patients with newly diagnosed T2DM. This issue has not
been studied previously and may help in resolving the ath-
erosclerotic complications resulting from intensive insulin
therapy in these patients. To our knowledge, this study is
the first to provide evidence that the plasma concentration
of sPLA2 is significantly decreased after short-term inten-
sive insulin therapy in patients with newly diagnosed
T2DM. The more sensitive change in sPLA2 levels could
be attributed to its role as an acute-phase protein [25]. Al-
though result of changes in Lp-PLA2 after treatment in all
diabetic patients was negative—which may be due to the
small sample size and short time of therapy or observa-
tion—the level of Lp-PLA2 was significantly decreased in
diabetic patients with macroangiopathy. Considering the
close relationship between Lp-PLA2 or sPLA2 and athero-
sclerosis, we believe that intensive insulin treatment could
alleviate inflammation in diabetic patients by decreasing
Fig. 2 Comparison of the Lp-PLA2 and sPLA2 levels between diabetic
patients with macroangiopathy and those without macroangiopathy
(133.43 [111.54, 145.17] ng/mL vs. 99.11 [63.02, 130.85] ng/mL, 235.73
[180.48, 416.46] ng/mL vs. 182.97 [90.08, 280.79] ng/mL, respectively) (a);
changes of the Lp-PLA2 and sPLA2 levels after continuous subcutaneous
insulin infusion (CSII) in all newly diagnosed type 2 diabetes (102.98
[76.34, 134.31] ng/mL vs. 88.35 [76.74, 125.18] ng/mL, 219.33 [130.03,
337.30] ng/mL vs. 173.78 [80.95, 278.09] ng/mL, respectively, n= 90) (b);
changes of the Lp-PLA2 and sPLA2 levels after CSII in diabetic patients
with or without macroangiopathy (Lp-PLA2: 133.43 [111.54, 145.17] ng/
mL vs 92.16 [80.26, 128.78] ng/mL, P <0.05; 99.11 [63.02, 130.85] ng/mL
vs. 85.94 [60.53, 119.76] ng/mL, P =0.102; sPLA2: 235.73 [180.48, 416.46]
ng/mL vs. 183.76 [93.88, 271.54] ng/mL, P < 0.01; 182.97 [90.08, 280.79]
ng/mL vs. 147.88 [76.58, 265.66] ng/mL, P< 0.05) (c). *P< 0.05, ** P< 0.01.
Values of P< 0.05 are statistically significant
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the levels of Lp-PLA2 and sPLA2, and such treatment may
further prevent or postpone the occurrence and progres-
sion of diabetic atherosclerotic complications.
As novel inflammatory markers, both Lp-PLA2 and
sPLA2 seem to be related with IR. Studies have suggested
that that the concentrations of Lp-PLA2 and sPLA2 are
high in patients with metabolic diseases accompanied by
IR, such as obesity [26, 27] and polycystic ovary syndrome
[28]. Kudolo et al. [29] detected the circulating levels of
plasma Lp-PLA2 in nine patients with obesity, six patients
with diabetes, and nine healthy controls and for the first
time, they showed that the Lp-PLA2 level was significantly
correlated with IR. Several studies thereafter observed a
similar relation between Lp-PLA2 or sPLA2 and IR, mainly
in people with normal blood glucose [11, 30]. Our study
indicated the same observations in patients with newly
diagnosed T2DM, and the correlation between sPLA2 and
IR in diabetic patients was illustrated for the first time. This
finding is supported by further results showing that the
decrease in both Lp-PLA2 and sPLA2 levels was positively
correlated with the reduction in HOMA-IR after intensive
insulin treatment. However, the definite relation of the
cause and effect between Lp-PLA2 or sPLA2 and IR is still
unclear. Numerous studies have shown that low-grade
chronic inflammation may induce or aggravate IR [31, 32].
Noto et al. [33] found that hydrolysis of oxidized phospho-
lipids by Lp-PLA2 produces FFA and lysolecithin, both of
which stimulate endothelial cells to generate inflammatory
cytokines and ultimately induce IR in both muscle and adi-
pose tissue. Furthermore, Iwase [34] and Huang et al. [35]
showed that metformin has the potential to improve IR in
a rat model of high-fat diet–induced non-alcoholic fatty
liver disease. This effect was due to the decrease in sPLA2
levels and inflammation. All the above mentioned studies
concluded that Lp-PLA2 or sPLA2 was responsible for the
IR. However, several studies have shown contrasting find-
ings. Kudolo et al. [29] believed that the levels of Lp-PLA2
in diabetic patients increased as a result of hyperinsuline-
mia. In addition, Ramanadham et al. [36] indicated that
sPLA2 is present within insulin secretory granules, and
stimulation of the Langerhan’s island with insulin secreta-
gogues leads to the co-secretion of insulin and sPLA2.
These researchers believe that hyperinsulinemia due to IR
increases the Lp-PLA2 or sPLA2 levels. Therefore, the
causal relationship between Lp-PLA2 or sPLA2 and IR is
still controversial, and further studies are needed to reach a
consensus on this issue.
In the current study, we did not observe any correlation
between the plasma Lp-PLA2 or sPLA2 levels and β-cell
function, irrespective of whether the influence of IR was
adjusted for. Mayer et al. found a positive association be-
tween Lp-PLA2 activity (not mass) and pancreatic β-cell
function [37]. However, studies with a larger sample size
are required to establish the association between the plasma
Lp-PLA2 or sPLA2 levels and pancreatic β-cell function.
Despite our important findings, there were several lim-
itations to this study. First, the number of patients en-
rolled in this study was insufficient and the short period
of intervention may have resulted in the absence of a
significant change in the Lp-PLA2 level after treatment.
Second, the Lp-PLA2 and sPLA2 levels in patients with
microvascular complications were not discussed because
only a few studies have thus far focused on the relation-
ship between microangiopathy and Lp-PLA2 or sPLA2.
Table 2 Correlations between Lp-PLA2, sPLA2 and clinical pa-
rameters in newly diagnosed type 2 diabetes
Lp-PLA2 (ng/ml) sPLA2 (ng/ml)
Body mass index (kg/m2) r = 0.121, P = 0.311 r = 0.123, P = 0.311
Waist circumference (cm) r = 0.023, P = 0.846 r = 0.243, P = 0.043*
Systolic pressure (mmHg) r = 0.080, P = 0.460 r = 0.046, P = 0.677
Diastolic pressure (mmHg) r = 0.077, P = 0.472 r = 0.079, P = 0.467
HbA1c (%) r = 0.283, P = 0.020* r = 0.076, P = 0.545
Total cholesterol (mmol/L) r = 0.224, P = 0.070 r = 0.147, P = 0.247
Triglyceride (mmol/L) r = 0.106, P = 0.448 r = 0.078, P = 0.584
HDL-C (mmol/L) r = 0.240, P = 0.072 r = 0.176, P = 0.199
LDL-C (mmol/L) r = 0.269, P = 0.029* r = 0.177, P = 0.162
HOMA-IR r = 0.309, P = 0.037* r = 0.506, P < 0.01**
HOMA-β r = −0.116, P = 0.353 r = −0.050, P = 0.670
IVGTT AUCIns r = −0.012, P = 0.294 r = −0.038, P = 0.742
IVGTT AUCPG r = 0.120, P = 0.338 r = 0.028, P = 0.809
AIR3–5 r = −0.029, P = 0.815 r = −0.006, P = 0.961
△Ins30/△G30 r = −0.023, P = 0.855 r = −0.055, P = 0.633
OGTT AUCIns r = −0.088, P = 0.483 r = −0.055, P = 0.635
OGTT AUCPG r = 0.049, P = 0.688 r = 0.042, P = 0.709
MBCI r = −0.099, P = 0.427 r = −0.206, P = 0.073
White blood cells (×109/L) r = 0.137, P = 0.262 r = 0.029, P = 0.796
Free fatty acid (umol/L) r = 0.167, P = 0.184 r = 0.096, P = 0.408
hsCRP (mg/L) r = 0.023, P = 0.852 r = 0.149, P = 0.189
Abbreviations: HbA1c hemoglobin A1c, IVGTT AUCGlu the areas under the curve
of glucose in intravenous glucose tolerance test, OGTT AUCGlu the areas under
the curve of glucose in oral glucose tolerance test, HDL-C high density
lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, hsCRP high
sensitivity C reactive protein; HOMA-IR, IAI, QUICKI and ISIced are indicators of
insulin sensitivity (HOMA-IR = FPG × FIns/22.5; IAI = 1/(FIns × FPG); QUICKI = 1/
(lgFPG + lgFIns); ISIced = MCR/LgMSI, MCR =M/MG, MG = (FPG + Glu30 min +
Glu60 min + Glu120 min)/4, MSI = (FIns + Ins30 min + Ins60 min + Ins120 min)/
4, M = 75000/120 + (FPG - Glu120 min) × 1.15 × 180 × 0.19 × body weight/120),
HOMA-β, AIR3–5 ΔIns30/ΔG30, MBCI, IVGTT AUCIns and OGTT AUCIns are
indicators of island function (HOMA-β = 20 × FIns/(FPG - 3.5); AIR3–5 is
calculated as the average increase of plasma insulin between the 3rd or 5th
minute and the base line in IVGTT; ΔIns30/ΔG30 = (Ins30min - FIns)/(Glu30min
- FPG); MBCI = (FPG × FIns)/(Glu120min + Glu60min - 7); AUCIns, the area under
the curve (AUC) of insulin, IVGTT AUCIns = (3 × FINS+ 5 × INS3+ 4 × INS5+ 5 ×
INS7+ 3 × INS10)/2, OGTT AUCIns = (FINS + 2 × INS30+ 3 × INS60+ 4 × INS120+
2 × INS180)/4; all the indicators regarding to β cell function were respectively
divided by HOMA-IR to guarantee from interference of insulin resistance),
Lp-PLA2 lipoprotein-associated phospholipase A2, sPLA2 secretory
phospholipase A2
Values of P < 0.05 are statistically significant
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Conclusions
In summary, the plasma Lp-PLA2 and sPLA2 levels
are increased in patients with newly diagnosed T2DM
and macroangiopathy as compared to those with
newly diagnosed T2DM but without macroangiopa-
thy. Early intensive insulin therapy can be effectively
used to achieve adequate glycemic control, improve
β-cell function and IR, and decrease plasma Lp-PLA2
and sPLA2 levels in patients with newly diagnosed
T2DM, especially in those with macroangiopathy. The
change in both the Lp-PLA2 and sPLA2 levels after CSII
were positively correlated with the change in HOMA-IR,
and Lp-PLA2 and sPLA2 levels are both independent fac-
tors that are positive correlated with IR in patients with
T2DM. Therefore, the decrease in Lp-PLA2 and sPLA2
levels by intensive insulin therapy might contribute to the
improvement of IR as well as protect from diabetic
atherosclerotic complications.
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Fig. 3 Correlation between ΔLp-PLA2 and ΔHOMA-IR in diabetic patients after CSII (r = 0.590, P < 0.05) (a); correlation between ΔsPLA2 and
ΔHOMA-IR in diabetic patients after CSII (r = 0.476, P < 0.05) (b). Values of P < 0.05 are statistically significant. ΔLp-PLA2, change in Lp-PLA2 levels;
ΔsPLA2, change in sPLA2 levels; ΔHOMA-IR, change in homeostatic model assessment for insulin resistance
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